- Home
- GBAB vs ALT Comparison
GBAB vs ALT Comparison
Compare GBAB & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBAB | ALT |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.4M | 415.3M |
| IPO Year | 2010 | 2005 |
Fundamental Metrics
Financial Performance| Metric | GBAB | ALT |
|---|---|---|
| Price | $14.87 | $3.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 75.5K | ★ 2.9M |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $756,308.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $14.35 | $2.91 |
| 52 Week High | $15.94 | $7.73 |
Technical Indicators
Market Signals| Indicator | GBAB | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 30.79 | 37.33 |
| Support Level | $14.85 | $3.40 |
| Resistance Level | $15.47 | $4.25 |
| Average True Range (ATR) | 0.14 | 0.23 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 11.42 | 18.41 |
Price Performance
Historical ComparisonAbout GBAB Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust of Beneficial Interest
Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust is a diversified closed-end management investment company. Its investment objective is to provide current income with a secondary objective of long-term capital appreciation. Its products include Mutual funds, Unit investment trusts, Closed-end funds, Rydex funds, Credit income fund and others.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.